THE FETAL GROWTH STUDY – A PROSPECTIVE COHORT STUDY OF FETAL GROWTH AND BODY COMPOSITION IN OVERWEIGHT AND OBESE PREGNANT WOMEN

Rosalie Mignon Grivell

B.Sc, B.M.B.S, FRANZCOG

Discipline of Obstetrics and Gynaecology School of Paediatrics and Reproductive Health Faculty of Health Sciences The University of Adelaide

A thesis submitted to The University of Adelaide for the degree of Doctor of Philosophy December 2011

TABLE OF CONTENTS

| TABLE OF CONTENTS | 2 |
|---|----|
| LIST OF TABLES | 5 |
| LIST OF FIGURES | 6 |
| LIST OF ABBREVIATIONS | 7 |
| ABSTRACT | 8 |
| | 10 |
| ACKNOWLEDGEMENTS | 11 |
| AUTHOR'S CONTRIBUTION | 12 |
| | 13 |
| | 13 |
| | 13 |
| | 13 |
| 1.2(2) THE SCOPE OF THE PROBLEM | 14 |
| 1.2(3) OVERWEIGHT AND OBESITY AND WOMEN'S HEALTH | 15 |
| 1.3 OVERWEIGHT AND OBESITY DURING PREGNANCY AND CHILDBIRTH | 16 |
| 1.3(1) THE SCOPE OF THE PROBLEM | 16 |
| 1.3(2) IMPLICATIONS FOR INFANT HEALTH AND BEYOND | 20 |
| 1.3(3) THE EFFECT OF GESTATIONAL WEIGHT GAIN IN WOMEN WHO ARE | |
| OVERWEIGHT OR OBESE ON MATERNAL AND INFANT HEALTH | 22 |
| 1.4 EFFECT OF OVERWEIGHT AND OBESITY ON FETAL GROWTH | 25 |
| 1.4(1) MECHANISMS FOR FETAL GROWTH IN MATERNAL OVERWEIGHT AND OBESITY | 25 |
| 1.4(2) MATERNAL OVERWEIGHT AND OBESITY AND FETAL GROWTH TRAJECTORIES | 26 |
| 1.5 ULTRASOUND PREDICTION OF MACROSOMIA AND CLINICAL OUTCOMES. | 28 |
| 1.6 FETAL AND NEONATAL BODY COMPOSITION | 32 |
| 1.7 RESEARCH GAPS IDENTIFIED AND AIMS OF THE FETAL | |
| GROWTH STUDY | 39 |
| 1.7(1) GAPS IN OUR CURRENT KNOWLEDGE IDENTIIFED FROM THIS | - |
| | 39 |
| | 41 |

| 2. METHODS | 41 |
|---|----|
| 2.1 THE LIMIT RANDOMISED TRIAL | 41 |
| 2.2 SPECIFIC METHODOLOGY FOR THE FETAL GROWTH STUDY | 42 |
| 2.2(1) ELIGIBILITY AND STUDY ENTRY | 42 |
| 2.2(2) ULTRASOUNDS MEASUREMENTS – BIOMETRY | 44 |
| 2.2(3) ULTRASOUND MEASUREMENTS – FETAL BODY COMPOSITION | 44 |
| 2.2(3)(i) Mid thigh total, lean and fat mass | 44 |
| 2.2(3)(ii) Anterior abdominal wall thickness/abdominal fat mass (AFM) | 45 |
| 2.2(3)(iii) Subscapular fat mass (SSFM) | 46 |
| 2.2(4) PRIMARY STUDY ENDPOINTS FOR THE FETAL GROWTH STUDY | 49 |
| 2.2(5) CLINICAL OUTCOMES FOR THE FETAL GROWTH STUDY | 50 |
| 2.2(6) SAMPLE SIZE FOR THE FETAL GROWTH STUDY | 51 |
| 2.2(7) DATA ANALYSIS FOR THE FETAL GROWTH STUDY | 51 |
| 2.2(7)(i) Study Entry, Pregnancy, Birth, and Infant Outcomes | 51 |
| 2.2(7)(ii) Fetal growth – calculation of Z-scores | 51 |
| 2.2(7)(iii) Fetal growth velocities | 52 |
| 2.2(7)(iv) Fetal body composition | 53 |
| 2.2(7)(v) Effect of BMI and gestational weight gain | 54 |
| 2.2(7)(vi) Correlation with clinical outcomes | 55 |
| 2.2(7)(vii) Prediction of clinical outcomes | 56 |
| | |

| 3.1 DESCRIPTION OF THE FETAL GROWTH STUDY COHORT | 57 |
|--|----|
| 3.2 FETAL GROWTH TRAJECTORIES | 60 |
| 3.3 RESULTS – THE EFFECT OF MATERNAL BMI AND GESTATIONAL | |
| WEIGHT GAIN | 69 |
| 3.4 CORRELATION WITH CLINICAL OUTCOMES | 72 |
| 3.5 PERFORMANCE OF FETAL GROWTH MEASURES IN THE PREDICTION | |
| OF MATERNAL AND INFANT OUTCOMES | 76 |
| 3.6 DISCUSSION | 79 |

| 3.6 (1) FETAL GROWTH AT 20, 28 AND 36 WEEKS | 79 |
|--|----|
| 3.6 (2) THE EFFECT OF BMI AND GESTATIONAL WEIGHT GAIN | 84 |
| 3.6 (3) CORRELATION WITH AND PREDICTION OF CLINICAL OUTCOMES | 85 |
| 3.6 (4) WHAT THIS STUDY ADDS | 90 |
| 3.6 (5) IMPLICATIONS FOR PRACTICE | 91 |
| 3.6 (6) IMPLICATIONS FOR RESEARCH | 91 |
| 3.6 (7) CONCLUSIONS | 92 |

| 4. RESULTS OF THE FETAL GROWTH STUDY 2 - FETAL BC COMPOSITION, THE EFFECT OF BMI AND GESTATIONAL WEIGHT |)DY |
|---|-----|
| GAIN AND CORRELATION WITH CLINICAL OUTCOMES | |
| 4.2 FETAL BODY COMPOSITION | |
| 4.3 THE EFFECT OF BMI AND GESTATIONAL WEIGHT GAIN | |
| | |
| 4.5 PERFORMANCE OF FETAL BODY COMPOSITION MEASURES | |
| IN THE PREDICTION OF MATERNAL AND INFANT OUTCOMES | 107 |
| 4.6 DISCUSSION | 109 |
| 4.6 (1) INTEROBSERVER VARIABILITY | 109 |
| 4.6 (2) FETAL BODY COMPOSITION AT 28 AND 36 WEEKS | 110 |
| 4.6 (3) THE EFFECT OF BMI AND GESTATIONAL WEIGHT GAIN | |
| 4.6 (4) CORRELATION WITH AND PREDICITON OF CLINICAL OUTCOMES | 113 |
| 4.6 (5) WHAT THIS STUDY ADDS | 115 |
| 4.6 (6) IMPLICATIONS FOR PRACTICE | 116 |
| 4.6 (7) IMPLICATIONS FOR RESEARCH | 116 |
| 4.6 (8) CONCLUSIONS | |
| 5. OVERALL CONCLUSIONS 5.1 FETAL GROWTH, THE EFFECT OF BMI AND GESTATIONAL WEIGHT GAIN | 117 |
| AND CORRELATION WITH CLINICAL OUTCOMES | 117 |

LIST OF TABLES

| Table 1.2(1) BMI categories as defined by The World Health Organisation | 14 |
|--|------|
| Table 1.3(1) Increased risk of adverse maternal outcomes in overweight and obese pregnant women compared with women of normal BMI | 18 |
| Table 1.3(2): Increased risk of adverse infant outcomes in overweight and obese pregnant women compared with women of normal BMI | 21 |
| Table 1.3(3) Updated IOM Recommendations for Total Weight Gain Range During Pregnancy, by Pre-pregnancy BMI | 23 |
| Table 3.1(1) Maternal Study Entry Characteristics for The Fetal Growth Study | 58 |
| Table 3.1(2) Maternal and infant outcomes for The Fetal Growth Study | 59 |
| Table 3.2(1) Ultrasound biometry Z-scores and distribution across percentile ranges from 20 to 36 weeks | 62 |
| Table 3.2(2) Growth velocities for biometric measures for The Fetal Growth Study compared with normal ranges | 63 |
| Table 3.3(1) Effect of BMI category on fetal growth biometry and growth velocity Z-scores | 70 |
| Table 3.3(2) Effect of Gestational weight gain on fetal growth biometry and growth velocity Z-scores. | . 71 |
| Table 3.4(1) Association between fetal growth and growth velocity Z-scores (above 90 th percentile) and birthweight | 74 |
| Table 3.4(2) Association between fetal growth Z-scores (above 90 th percentile) and clinical outcomes | 75 |
| Table 3.5(1) Performance of fetal biometry and growth velocity (above the 90 th percentile) in the prediction of macrosomia | 77 |
| Table 3.5(2) Performance of fetal biometry and growth velocity (above the 90 th percentile) in the prediction of clinical outcomes | 78 |
| Table 4.1 Intraclass correlation coefficients (ICC) for measures of fetal body composition at28 and 36 weeks with corresponding level of agreement | 93 |
| Table 4.2 Fetal body composition measures and comparison with normal ranges | 96 |
| Table 4.3(1) Effect of BMI category on fetal body composition | 102 |
| Table 4.3(2) Effect of Gestational weight gain category on fetal body composition | 103 |
| Table 4.4(1) Association between fetal body composition (above 95th percentile) and infant birthweight | 105 |
| Table 4.4(2) Association between fetal body composition (above 95 th percentile) and clinical outcomes | 106 |
| Table 4.5(1) Performance of fetal biometry and growth velocity (above the 90 th percentile) in the prediction of macrosomia and clinical outcomes | 108 |

LIST OF FIGURES

| Figure 2.1 (1) Ultrasound measurement time points for The Fetal Growth Study | 43 |
|---|-----|
| Figure 2.2(3)(i) Diagrammatic representation and ultrasound example of longitudinal and cross sectional view of the femur used to measure MTTM and MTLM | 46 |
| Figure 2.2(3)(ii) Diagrammatic representation of the abdominal circumference view used to obtain the AFM measurement and subsequent magnification view used to measure the AFM with ultrasound example. | 47 |
| Figure 2.2(3)(iii) Diagrammatic representation and ultrasound example of the view used to measure the subscapular fat mass | |
| Figure 3.1(1) Fetal Growth Study flow chart | 57 |
| Figure 3.2(1) Biparietal diameter Z-score distribution by percentile ranges | 64 |
| Figure 3.2(2) Head circumference Z-score distribution by percentile ranges | 65 |
| Figure 3.2(3) Abdominal circumference Z-score distribution by percentile ranges | 66 |
| Figure 3.2(4) Femur length Z-score distribution by percentile ranges | 67 |
| Figure 3.2(5) Estimated fetal weight Z-score distribution by percentile ranges | 68 |
| Figure 4.2(1) Study flow chart – fetal body composition measures obtained | 94 |
| Figure 4.2(2) Mid thigh fat mass distribution by percentile ranges | 97 |
| Figure 4.2(3) Mid thigh lean mass distribution by percentile ranges | 98 |
| Figure 4.2(4) Abdominal fat mass distribution by percentile ranges | 99 |
| Figure 4.2(5) Subscapular fat mass distribution by percentile ranges | 100 |

LIST OF ABBREVIATIONS

- AC : abdominal circumference
- AA : abdominal area
- AFM : abdominal fat mass
- BPD : biparietal diameter
- BMI : body mass index
- CS : caesarean section
- EFW : estimated fetal weight
- FL : femur length
- GDM : gestational diabetes mellitus
- GWG : gestational weight gain
- HC : head circumference
- IOL : induction of labour
- IOM : Institute of Medicine
- LGA : large for gestational age
- LR : likelihood ratio
- LR+ : positive likelihood ratio
- LR-: negative likelihood ratio
- MTFM : mid thigh fat mass
- MTLM : mid thigh lean mass
- MTTM : mid thigh total mass
- NICU : neonatal intensive care
- PCOS : polycystic ovarian syndrome
- PEAPOD : air displacement plethysmography
- ROC curve : receiver operating characteristic curves
- SSFM : subscapular fat mass
- TOBEC : total body electrical conductivity
- WHO : World Health Organisation

ABSTRACT

Background

Maternal overweight and obesity pose significant risks both for the woman and her infant, including high infant birthweight. Gestational weight gain may also be an important factor in determining pregnancy outcomes. The effect of high maternal BMI and gestational weight gain on fetal growth and fetal body composition with reference to population standards has not been well described to date.

Aims

The aim of The Fetal Growth Study was to describe fetal growth and body composition prospectively in a large group of overweight and obese women during pregnancy and to examine the influence of maternal BMI and gestational weight gain on these measures.

Methods

Fetal biometric growth measures (biparietal diameter, head circumference, abdominal circumference, femur length and estimated fetal weight) and fetal body composition (mid thigh lean and fat mass, abdominal fat mass and subscapular fat mass) were assessed prospectively using ultrasound at 28 and 36 weeks' gestation. Important maternal and fetal outcomes were collected including gestational weight gain and infant birthweight.

Results

The findings of The Fetal Growth Study indicate that maternal overweight and obesity is significantly associated with increased fetal growth, an effect that is evident from 20 weeks' gestation when compared with published normal values. Additionally, when compared with population standards, the relative contributions of head and abdominal growth change throughout pregnancy with abdominal growth dominating in the second trimester and head growth in the third trimester. Both maternal BMI

category and gestational weight gain contribute to increased measures of fetal growth, predominantly through a modification of abdominal and overall growth. Gestational weight gain above current recommendations was associated with further increases in abdominal and overall growth. Maternal overweight and obesity is associated with a significant increase in fetal measures of both lean and fat mass. At 28 and 36 weeks, AC and EFW growth were associated with birthweight above 4500g, whilst HC was associated with birthweight above 4000g but not 4500g.

Furthermore, EFW, head and abdominal growth were associated with mode of birth, with measures above the 90th percentile increasing the likelihood of caesarean section for women. The only predictor of clinical outcomes with a moderately useful positive likelihood ratio was fetal AC above the 90th percentile at 28 weeks (LR+ 6.56 for birthweight above 4500g, LR- 0.37).

Conclusions

Maternal overweight or obesity and gestational weight gain above recommended ranges influence fetal growth and fetal body composition from mid pregnancy. Gestational weight gain above current recommended ranges is associated with a further increase in measures of fetal growth and fetal fat mass. In women who are overweight or obese, growth above the 90th percentile in the third trimester is associated with high infant birthweight and an increased likelihood of caesarean section. Further research from ongoing prospective intervention studies will provide important information regarding the effect of limiting weight gain on fetal growth and body composition and important maternal and infant outcomes.

DECLARATION

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution to Rosalie Mignon Grivell and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis, when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library catalogue, and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Rosalie Mignon Grivell 21st December 2011

ACKNOWLEDGEMENTS

I am immensely grateful to my supervisors Prof Jodie Dodd and Prof Caroline Crowther for their supervision, support and encouragement during the course of my PhD. Jodie's enthusiasm for and dedication to clinical research has been and will continue to be an inspiration. Caroline's generosity of time and spirit, and positive counsel has been invaluable throughout the time we have worked together.

I believe that without the influence and example of Prof Judy Searle and A/Prof John Svigos I would not have embarked upon and continued on my current career path, I am lucky to have had such great academic mentors.

During my candidature I was supported by a University of Adelaide APA postgraduate award and the RANZCOG Research Foundation's Fotheringham Research Fellowship. The study also received support from the Channel 7 Children's Research Foundation. I am also appreciative of the support received through the Robinson Institute's mentoring program and Kay Hannaford Seamark.

I particularly thank Andrea Deussen and the outstanding LIMIT research team for their contribution and organisational assistance in coordinating so many busy ultrasound lists. Thanks also to the women who participated in the study.

I also thank Dr Casie Staehr, Dr Rachel Earl, Dr Nayana Parange and Dr Merlyn Pinto Barreto for their assistance in performing ultrasounds.

To those who have given endless belief, support and friendship over the last 3 1/2 years; Michele, Jane, Susie, Monique, Mojgan, Adele, Casie, Nicola, Kylie, Tina, Bec and Kate – I am forever grateful.

To my family, Mignon, Jeff, Kelvin and Skye, thank you for your constant love, support and understanding.

Finally, thanks to God, whose grace and mercy amaze me.

For Maya, Amelie, Macauley and Elsa - you inspire me to greatness and humility.

AUTHOR'S CONTRIBUTION

I have been responsible for the development of the original fetal ultrasound protocols and methodology including the assessment of fetal body composition and obtaining research and ethics approval. I developed the ultrasound data collection sheets and coordinated the collection of all ultrasound data. I was responsible for training all research sonographers and for maintaining quality control. I personally performed 80% of the ultrasound examinations included in this thesis, including the assessment of interobserver variability. I have received statistical advice from Dr Helena Oakey regarding the analysis of interobserver variability. I conducted all other statistical analyses presented and accept responsibility for the veracity of the statistical analyses and their interpretation.